Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies

The prognostic value of minimal residual disease (MRD) in Philadelphia-chromosome-positive (Ph+) childhood acute lymphoblastic leukemia (ALL) treated with tyrosine kinase inhibitors is not fully established. We detected MRD by real-time quantitative polymerase chain reaction (RQ-PCR) of rearranged i...

Full description

Saved in:
Bibliographic Details
Published in:Haematologica
Main Authors: Cazzaniga, Giovanni, De Lorenzo, Paola, Alten, Julia, Röttgers, Silja, Hancock, Jeremy, Saha, Vaskar, Castor, Anders, Madsen, Hans O., Gandemer, Virginie, Cavé, Hélène, Leoni, Veronica, Köhler, Rolf, Ferrari, Giulia M., Bleckmann, Kirsten, Pieters, Rob, van der Velden, Vincent, Stary, Jan, Zuna, Jan, Escherich, Gabriele, zur Stadt, Udo, Aricò, Maurizio, Conter, Valentino, Schrappe, Martin, Valsecchi, Maria Grazia, Biondi, Andrea
Format: Artigo
Language:Inglês
Published: Ferrata Storti Foundation 2018
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5777198/
https://ncbi.nlm.nih.gov/pubmed/29079599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.176917
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items